UBS Group
BHVN

UBS Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

UBS Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-833,464
Closed -$126M – 12042
2022
Q3 		$126M Buy
833,464
+559,438
+204% +$82.9M 0.06% 342
2022
Q2 		$39.9M Buy
274,026
+236,397
+628% +$30.2M 0.02% 866
2022
Q1 		$4.46M Buy
37,629
+25,883
+220% +$3.23M ﹤0.01% 2643
2021
Q4 		$1.62M Buy
11,746
+5,701
+94% +$725K ﹤0.01% 3930
2021
Q3 		$839K Buy
6,045
+1,506
+33% +$188K ﹤0.01% 4336
2021
Q2 		$441K Sell
4,539
-34,821
-88% -$2.83M ﹤0.01% 4824
2021
Q1 		$2.69M Buy
39,360
+18,100
+85% +$1.46M ﹤0.01% 3252
2020
Q4 		$1.82M Buy
21,260
+19,757
+1,315% +$1.67M ﹤0.01% 3482
2020
Q3 		$98K Sell
1,503
-440
-23% -$28.8K ﹤0.01% 5202
2020
Q2 		$142K Buy
1,943
+795
+69% +$42.3K ﹤0.01% 5057
2020
Q1 		$39K Buy
1,148
+164
+17% +$7.5K ﹤0.01% 6034
2019
Q4 		$54K Sell
984
-101,495
-99% -$5.03M ﹤0.01% 6317
2019
Q3 		$4.28M Buy
102,479
+95,576
+1,385% +$4.04M ﹤0.01% 2540
2019
Q2 		$302K Buy
6,903
+2,726
+65% +$154K ﹤0.01% 4658
2019
Q1 		$215K Sell
4,177
-8,501
-67% -$367K ﹤0.01% 4563
2018
Q4 		$469K Sell
12,678
-1,343
-10% -$48.4K ﹤0.01% 4325
2018
Q3 		$527K Buy
14,021
+10,661
+317% +$392K ﹤0.01% 4361
2018
Q2 		$133K Buy
3,360
+1,046
+45% +$33.2K ﹤0.01% 5247
2018
Q1 		$60K Sell
2,314
-245
-10% -$7.33K ﹤0.01% 5589
2017
Q4 		$69K Buy
2,559
+2,190
+593% +$60.3K ﹤0.01% 5607
2017
Q3 		$14K Buy
+369
New +$11.2K ﹤0.01% 6724

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

UBS Group's BHVN Position: Q4 2022 in Review

UBS Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 833,464 shares — an estimated $126M sold.

UBS Group first reported a position in BHVN in Q3 2017 and held it in 21 quarters. The position peaked at $126M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • UBS Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 833,464 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $126M.
  • UBS Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 21 quarters.
  • UBS Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $126M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.